Aptevo reports 93% benefit in TP53‑mutated AML
APVO announces strong early remission data for mipletamig in high‑risk TP53‑mutated AML and outlines next clinical and regulatory milestones.
Rhea-AI Filing Summary
Aptevo Therapeutics Inc. (APVO) reported new early clinical data for its lead candidate mipletamig in frontline acute myeloid leukemia (AML) patients with TP53 mutations, a historically hard-to-treat subgroup. In 14 evaluable patients treated with mipletamig plus venetoclax and azacitidine, 13 patients (93%) showed clinical benefit, and 11 patients (79%) achieved complete remission or complete remission with incomplete hematologic recovery, including 9 complete remissions. The composite remission rate compares with a published 41% remission rate for venetoclax plus azacitidine alone in a similar high‑risk population. The ongoing RAINIER Phase 1b/2 trial is in the dose-optimization phase, which is expected to complete by year-end, with regulatory interaction planned in the first half of 2027 to determine next steps. Mipletamig has orphan drug designation in AML, and Aptevo continues to advance a broader pipeline of bispecific and trispecific immunotherapies and radiopharmaceutical programs.
Positive
- Strong early efficacy signal: mipletamig triplet showed a 93% clinical benefit rate and 79% CR/CRi in TP53‑mutated frontline AML, comparing favorably to a published 41% composite remission rate for venetoclax plus azacitidine alone in a similar high‑risk population.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Clinical benefit rate: 93%
CR/CRi rate: 79%
Complete remissions: 9 patients
+5 more
8 metrics
Clinical benefit rate
93%
Mipletamig triplet in 14 evaluable TP53‑mutated frontline AML patients
CR/CRi rate
79%
11 of 14 TP53‑mutated AML patients achieved CR or CRi
Complete remissions
9 patients
Number of complete remissions among 14 evaluable TP53‑mutated AML patients
Patients with clinical benefit
13 of 14 patients
TP53‑mutated frontline AML patients treated with mipletamig triplet
Benchmark remission rate
41%
Published composite remission rate for venetoclax plus azacitidine in similar TP53‑mutated AML
Regulatory interaction timing
First half of 2027
Planned regulatory interaction after completion of RAINIER dose-optimization phase
RAINIER trial phase
Phase 1b/2
Dose optimization, multi-center, multi-cohort, open-label frontline AML study
Orphan drug designation
Granted for AML
Mipletamig designation under the Orphan Drug Act
Key Terms
clinical benefit rate, complete remission, TP53-mutated AML, orphan drug designation, +2 more
6 terms
clinical benefit rate medical
"announced a 93% clinical benefit rate with its mipletamig triplet"
The clinical benefit rate is the share of patients in a medical study who experience a meaningful positive treatment effect — usually tumor shrinkage, disappearance, or disease staying stable for a set period — rather than their condition worsening. Investors care because it gives a broader picture of a therapy’s real-world usefulness beyond quick responses, like judging how many cars in a road test actually arrive without breaking down, which helps predict commercial and regulatory prospects.
complete remission medical
"Eleven patients achieved CR or CRi (79%), including nine complete remissions"
Complete remission means that medical tests and exams show no detectable signs or symptoms of a disease after treatment, though it does not guarantee the disease is permanently gone. Investors care because complete remission rates are a clear, measurable outcome used by regulators and doctors to judge a therapy’s effectiveness; like a fire appearing fully extinguished, it can boost a drug’s perceived value and commercial prospects while still requiring ongoing monitoring.
TP53-mutated AML medical
"TP53-mutated AML remains one of the most challenging AML subpopulations"
orphan drug designation regulatory
"Mipletamig has received orphan drug designation for AML"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Phase 1b/2 medical
"RAINIER, a frontline AML study, is a Phase 1b/2 dose optimization"
Phase 1b/2 is a combined early-stage human study that first checks a drug’s safety and side effects in a small group and then expands to test whether it shows signs of working in patients. Think of it as a product test that first confirms it’s safe to use, then looks for early evidence of benefit; positive results can significantly reduce clinical risk and increase a company’s value, while negative results raise the opposite.
trispecific immunotherapy medical
"advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors"
FAQ
What key AML efficacy results did Aptevo Therapeutics (APVO) report for mipletamig?
Aptevo reported a 93% clinical benefit rate in 14 evaluable TP53‑mutated frontline AML patients treated with mipletamig plus venetoclax and azacitidine, with 11 patients (79%) achieving CR or CRi, including nine complete remissions.
How do APVO’s mipletamig AML results compare to venetoclax plus azacitidine alone?
The mipletamig triplet showed a 79% CR/CRi rate, which the company states compares favorably to a published 41% composite remission rate for venetoclax plus azacitidine in treatment‑naïve poor‑risk, TP53‑mutated AML patients.
How many TP53‑mutated AML patients were included in Aptevo’s mipletamig analysis?
The analysis included 14 evaluable TP53‑mutated frontline AML patients treated with mipletamig in combination with venetoclax and azacitidine, including two patients from a previously completed dose expansion trial.
What are the next clinical and regulatory milestones for APVO’s RAINIER trial?
The RAINIER Phase 1b/2 trial is in dose optimization and is expected to be completed by year-end, with regulatory interaction planned for the first half of 2027 to determine subsequent development steps.
What is mipletamig and what special designations does it have for APVO?
Mipletamig is Aptevo’s wholly owned lead proprietary drug candidate targeting AML via CD123-expressing leukemic cells. It has received orphan drug designation for AML under the Orphan Drug Act.
What other pipeline programs does Aptevo Therapeutics (APVO) highlight?
Aptevo highlights APVO451, a trispecific solid tumor candidate, and a collaboration with Niowave to develop up to three radiopharmaceutical oncology programs, including a first program targeting nectin-4, with two preclinical molecules expected to enter IND‑enabling studies in 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
